Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: Overview of RIO studies;Le rimonabant améliore le profil de risque cardio-métabolique chez le sujet obèse ou en surpoids: Synthèse des études «RIO»

Revue Medicale Suisse

Volumn 2, Issue 76, 2006, Pages 1916-1923

  Scheen, André J ^a   Van Gaal, Luc G ^b   Després, Jean Pierre ^c   Pi Sunyer, Xavier ^d   Golay, Alain ^e   Hanotin, Christine ^f  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c LAVAL UNIVERSITY   (Canada)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e HUG   (Sweden)

^f SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; RIMONABANT; SULFONYLUREA; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; HUMANS; METABOLIC SYNDROME X; OBESITY; OVERWEIGHT; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CANNABINOID;

EID: 33748937876     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Grundy SM. The changing face of cardiovascular risk. J Am Coll Cardiol 2005;46:173-5.
2. Alberti KGMM, Lefèbvre P (Eds). Type 2 diabetes and the metabolic syndrome in Europe. Eur Heart J 2005;7(Suppl. D):D1-D26.
3. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20.
4. Klein S, Burke LE, Bray G A, et al. Clinical implications of obesity with specific focus on cardiovascular disease: A statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-67.
5. Scheen AJ. Current management strategies for co-existing diabetes mellitus and obesity. Drugs 2003;63:1165-84.
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
7. Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol 2004;29:31-45.
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
9. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.
10. Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Invest Drugs 2004;5:389-94.
11. Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005;37:270-5.
12. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100.
13. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-43.
14. Makoundou V, Golay A. Nouveau traitement de l'obésité et du syndrome métabolique: le rimonabant. Rev Med Suisse 2006;2:41-5.
15. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
16. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: A randomized controlled trial. JAMA 2006;295:761-75.
17. Després JP, Golay A, Sjöström L. Rimonabant in Obesrty-Lipids Study Group. Effects on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
18. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, for the RIO-Diabetes Study Group. Effects of rimonabant on body weight, glucose control, and cardiometabolic risk factors in patients with type 2 diabetes. 2006 submitted.
19. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.
20. Pi-Sunyer F-X, Després J-P, Scheen A, Van Gaal L. Improvement of metabolic effects with rimonabant beyond the effect attributable to weight loss alone: Pooled one year data from the RIO (Rimonabant In Obesity and Related Metabolic Disorders) program (abstract). JACC 2006;47(Suppl. A),362-A.
21. Kolotkin RL, Crosby RD, Scheen A, Golay A, Després J-P. Effect of rimonabant on quality of life in overweight/obese patients. Congress of the International Society for Pharmacoeconomics Outcomes and Research (IPSOR), Philadelphia, US, 22 May 2006.